[Federal Register Volume 59, Number 92 (Friday, May 13, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-11641]
[[Page Unknown]]
[Federal Register: May 13, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Committee Meeting; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration is announcing an amendment to
the notice of a meeting of the Biological Response Modifiers Advisory
Committee which is scheduled for May 25 and 26, 1994. This meeting was
announced in the Federal Register of April 15, 1994 (59 FR 18134 at
18135). The amendment is being made to remove one agenda item and to
remove the closed committee deliberations portion from the meeting.
There are no other changes. This amendment will be announced at the
beginning of the open portion of the meeting.
FOR FURTHER INFORMATION CONTACT: William Freas or Pearline Muckelvene,
Center for Biologics Evaluation and Research (HFM-21), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-594-1054.
SUPPLEMENTARY INFORMATION: In the Federal Register of April 15, 1994,
FDA announced that a meeting of the Biological Response Modifiers
Advisory Committee would be held on May 25 and 26, 1994. On page 18135,
in the third column, under ``Type of meeting and contact person'' and
``Open committee discussion'' portions of the agenda are amended to
read as follows:
Type of meeting and contact person. Open public hearing, May 25,
1994, 10:30 a.m. to 11:15 a.m., unless public participation does not
last that long; open committee discussion, 11:15 a.m. to 5:30 p.m.;
open public hearing, May 26, 1994, 8 a.m. to 8:45 a.m., unless public
participation does not last that long; open committee discussion, 8:45
a.m. to 3 p.m.; William Freas or Pearline Muckelvene, Center for
Biologics Evaluation and Research (HFM-21), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-594-1054.
Open committee discussion. The committee will discuss issues
related to the safety and efficacy of hematopoietic support regimens in
the setting of myelotoxic chemotherapy.
Dated: May 9, 1994.
Linda A. Suydam,
Interim Deputy Commissioner for Operations.
[FR Doc. 94-11641 Filed 5-12-94; 8:45 am]
BILLING CODE 4160-01-F
